The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial
Launched by UNIVERSITY OF MANITOBA · Apr 13, 2013
Trial Information
Current as of May 20, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age: 15-45 years old
- • Have lived with type 1 diabetes for at least 2 years
- • HbA1c \<9.9%
- • Currently physically inactive (\<150 minutes of self-reported structured physical activity per week)
- • Undergone a resting ECG to screen for left ventricular hypertrophy, arrhythmias or signs or coronary artery disease that may be exacerbated with vigorous intensity exercise
- Exclusion Criteria:
- • Have frequent and unpredictable hypoglycaemia
- • Had a change in insulin management strategy, including adoption of a pump, within 2 months of enrolment
- • Are currently participating in structured activity or sport-related activities
- • Are women who are pregnant or planning to get pregnant within the 12 months of the trial and those who are breastfeeding
- • Have conditions that would render physical activity contraindicated including: uncontrolled hypertension (BP\>150mmHg systolic or \>95mmHg diastolic in a sitting position); severe peripheral neuropathy; history of cardiovascular disease
- • Have a cognitive deficit resulting in an inability to provide informed consent
- • Currently taking beta blockers
- • Currently taking atypical antipsychotics or corticosteroids
About University Of Manitoba
The University of Manitoba, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive expertise in medical research, public health, and community engagement to conduct rigorous and ethical clinical studies. The institution aims to translate scientific findings into practical applications that enhance patient care and improve health outcomes. Committed to fostering a culture of excellence and integrity, the University of Manitoba prioritizes participant safety and scientific validity in all its clinical research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamilton, Ontario, Canada
Calgary, Alberta, Canada
Ottawa, Ontario, Canada
Winnipeg, Manitoba, Canada
Edmonton, Alberta, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials